The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy

被引:25
作者
Kurbegovic, Sorel [1 ]
Berg, Kasper Drimer [1 ]
Thomsen, Frederik Birkebaek [1 ]
Gruschy, Lisa [1 ]
Iversen, Peter [1 ]
Brasso, Klaus [1 ]
Roder, Martin Andreas [1 ]
机构
[1] Copenhagen Univ Hosp, Dept Urol, Rigshosp, Copenhagen Prostate Canc Ctr, Copenhagen N, Denmark
关键词
Radical prostatectomy; competing-risk; biochemical recurrence; intermediate-risk; D'Amico; 2005; INTERNATIONAL-SOCIETY; ISUP CONSENSUS CONFERENCE; BEAM RADIATION-THERAPY; ACTIVE SURVEILLANCE; SURVIVAL RATES; CLASSIFICATION; PROGRESSION; CARCINOMA; DISEASE; SCORE;
D O I
10.1080/21681805.2017.1356369
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To report oncological outcomes including biochemical recurrence (BR) following radical prostatectomy (RP) from a large consecutive cohort operated in an 18-year period. Additionally, an in-depth analysis of outcomes among D'Amico intermediate-risk patients is presented.Materials and methods: A total of 2,091 patients with PCa who underwent RP at Department of Urology, Rigshospitalet, Copenhagen, Denmark between 1995 and 2013 were included. Univariate and multiple cause-specific Cox regression analyses for BR were applied using competing risk models. Death prior to BR was considered a competing event. BR was defined as the first PSA 0.2ng/ml. No patient received adjuvant therapy prior to BR.Results: Overall, the 5- and 10-years cumulative incidence of BR was 21.9% and 32.0%. The 10-year cumulative incidence of BR was 17.9%, 31.9% and 47.9% for D'Amico low-, intermediate- and high-risk patients, respectively. Among intermediate-risk patients, the 10-year cumulative incidence of BR was 24.0%, 39.9%, and 47.9% for patients harboring one, two or three risk factors, respectively (Gray test: p<0.0001). In multivariate analysis, PSA, RP GS, pT category, and positive surgical margins were significantly associated with an increased risk of BR.Conclusions: The risk of BR among patients with intermediate-risk disease is not uniform and is highly dependent on the number of risk factors per patient. Intermediate-risk patients have a comparable risk of recurrence as high-risk patients, and this should be taken into consideration when counseling patients prior to RP.
引用
收藏
页码:450 / 456
页数:7
相关论文
共 34 条
[1]   The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up [J].
Antonarakis, Emmanuel S. ;
Feng, Zhaoyong ;
Trock, Bruce J. ;
Humphreys, Elizabeth B. ;
Carducci, Michael A. ;
Partin, Alan W. ;
Walsh, Patrick C. ;
Eisenberger, Mario A. .
BJU INTERNATIONAL, 2012, 109 (01) :32-39
[2]   Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial [J].
Aus, G ;
Abrahamsson, PA ;
Ahlgren, G ;
Hugosson, J ;
Lundberg, S ;
Schain, M ;
Schelin, S ;
Pedersen, K .
BJU INTERNATIONAL, 2002, 90 (06) :561-566
[3]   The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading - a matched-pair analysis [J].
Berg, Kasper D. ;
Thomsen, Frederik B. ;
Nerstrom, Camilla ;
Roder, Martin A. ;
Iversen, Peter ;
Toft, Birgitte G. ;
Vainer, Ben ;
Brasso, Klaus .
BJU INTERNATIONAL, 2016, 117 (06) :883-889
[4]   Early biochemical recurrence, urinary continence and potency outcomes following robot-assisted radical prostatectomy [J].
Berg, Kasper Drimer ;
Thomsen, Frederik Birkebek ;
Hvarness, Helle ;
Christensen, Ib Jarle ;
Iversen, Peter .
SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (04) :356-366
[5]   Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer [J].
Bill-Axelson, Anna ;
Holmberg, Lars ;
Garmo, Hans ;
Rider, Jennifer R. ;
Taari, Kimmo ;
Busch, Christer ;
Nordling, Stig ;
Haggman, Michael ;
Andersson, Swen-Olof ;
Spangberg, Anders ;
Andren, Ove ;
Palmgren, Juni ;
Steineck, Gunnar ;
Adami, Hans-Olov ;
Johansson, Jan-Erik .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (10) :932-942
[6]   Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy [J].
Boorjian, Stephen A. ;
Karnes, R. Jeffrey ;
Rangel, Laureano J. ;
Bergstralh, Eric J. ;
Blute, Michael L. .
JOURNAL OF UROLOGY, 2008, 179 (04) :1354-1360
[7]  
BRASSO M, 2001, UGESKRIFT LAEGER, V163, P5669
[8]   The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy [J].
Cooperberg, MR ;
Pasta, DJ ;
Elkin, EP ;
Litwin, MS ;
Latini, DM ;
DuChane, J ;
Carroll, PR .
JOURNAL OF UROLOGY, 2005, 173 (06) :1938-1942
[9]   Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Cote, K ;
Loffredo, M ;
Schultz, D ;
Chen, MH ;
Tomaszewski, JE ;
Renshaw, AA ;
Wein, A ;
Richie, JP .
CANCER, 2002, 95 (02) :281-286
[10]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974